In vivo antitumor effect of a novel inhibitor of protein geranylgeranyltransferase-I

Molecular Cancer Therapeutics

Volumn 8, Issue 5, 2009, Pages 1218-1226

  Lu, Jie ^a,b   Chan, Lai ^a   Fiji, Hannah D G ^a   Dahl, Russell ^c   Kwon, Ohyun ^a,b   Tamanoi, Fuyuhiko ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c BURNHAM INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ANTINEOPLASTIC AGENT; ASPARTATE AMINOTRANSFERASE; GERANYLGERANYLTRANSFERASE I; GERANYLGERANYLTRANSFERASE I INHIBITOR; P 61A6; PROTEIN; RAP1 PROTEIN; RHOA GUANINE NUCLEOTIDE BINDING PROTEIN; UNCLASSIFIED DRUG;

ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIANGIOGENIC ACTIVITY; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CANCER CELL; CANCER INHIBITION; CANCER THERAPY; CELL CYCLE ARREST; CELL CYCLE G1 PHASE; CELL GROWTH; CELL LINE; CELL PROLIFERATION; CELLULAR DISTRIBUTION; CONTROLLED STUDY; DISTRIBUTION VOLUME; DOSE RESPONSE; DRUG CLEARANCE; DRUG DOSE REDUCTION; DRUG HALF LIFE; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; FEMALE; GROWTH INHIBITION; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VIVO STUDY; MAXIMUM PLASMA CONCENTRATION; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; PANCREAS CANCER; PRENYLATION; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS INHIBITION; TUMOR GROWTH; TUMOR XENOGRAFT;

ALKYL AND ARYL TRANSFERASES; ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL LINE, TUMOR; ENZYME INHIBITORS; FEMALE; HUMANS; MICE; MICE, SCID; PANCREATIC NEOPLASMS; PROTEIN PRENYLATION; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 66849109067     PISSN: 15357163     EISSN: None     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-08-1122     Document Type: Article

References (33)

1. Tamanoi F, Sigman DS. The enzymes. Vol.21. San Diego: Academic Press; 2001.
2. Xue W, Krasnitz A, Lucito R, et al. DLC1 is a chromosome 8p tumor suppressor whose loss promotes hepatocellular carcinoma. Genes Dev 2008;22:1439-1444
3. Lahoz A, Hall A. DLC1: a significant GAP in the cancer genome. Genes Dev 2008;22:1724-1730
4. Clark EA, Golub TR, Lander ES, Hynes RO. Genomic analysis of metastasis reveals an essential role for RhoC. Nature 2000;406:532-535 (Pubitemid 30625739)
5. Hakem A, Sanchez-Sweatman O, You-Ten A, et al. RhoC is dispensable for embryogenesis and tumor initiation but essential for metastasis. Genes Dev 2005;19:1974-1979 (Pubitemid 41247955)
6. Lim KH, Baines AT, Fiordalisi JJ, et al. Activation of RalA is critical for Ras-induced tumorigenesis of human cells. Cancer Cell 2005;7:533-545 (Pubitemid 40799247)
7. Khosravi-Far R, Cox AD, Kato K, Der CJ. Protein prenylation: key to ras function and cancer intervention? Cell Growth Differ 1992;3:461-469
8. Lane KT, Beese LS. Thematic review series: lipid posttranslational modifications. Structural biology of protein farnesyltransferase and geranylgeranyltransferase type I. J Lipid Res 2006;47:681-699
9. Leung KF, Baron R, Seabra MC. Thematic review series: lipid posttranslational modifications. Geranylgeranylation of Rab GTPases. J Lipid Res 2006;47:467-475
10. Winter-Vann AM, Casey PJ. Post-prenylation-processing enzymes as new targets in oncogenesis. Nat Rev Cancer 2005;5:405-412 (Pubitemid 40637832)
11. Gelb MH, Brunsveld L, Hrycyna CA, et al. Therapeutic intervention based on protein prenylation and associated modifications. Nat Chem Biol 2006;2:518-528 (Pubitemid 44413234)
12. Sjogren AK, Andersson KM, Liu M, et al. GGTase-I deficiency reduces tumor formation and improves survival in mice with K-RAS-induced lung cancer. J Clin Invest 2007;117:1294-1304 (Pubitemid 46718417)
13. 1 and induces p21(WAF1/CIP1/SDI1) in a p53-independent manner. J Biol Chem 1997;272:27224-27229
14. Kusama T, Mukai M, Tatsuta M, et al. Selective inhibition of cancer cell invasion by a geranylgeranyltransferase-I inhibitor. Clin Exp Metastasis 2003;20:561-567 (Pubitemid 37297185)
15. Sun J, Ohkanda J, Coppola D. Geranylgeranyltransferase I inhibitor GGTI-2154 induces breast carcinoma apoptosis and tumor regression in H-Ras transgenic mice. Cancer Res 2003;63:8922-8929 (Pubitemid 38064072)
16. Peterson YK, Kelly P, Weinbaum CA, Casey PJ. A novel protein geranylgeranyltransferase-I inhibitor with high potency, selectivity, and cellular activity. J Biol Chem 2006;281:12445-12450 (Pubitemid 43855330)
17. Falsetti SC, Wang DA, Peng H, et al. Geranylgeranyltransferase I inhibitors target RalB to inhibit anchorage-dependent growth and induce apoptosis and RalA to inhibit anchorage-independent growth. Mol Cell Biol 2007;27:8003-8014 (Pubitemid 350086432)
18. Watanabe M, Fiji HD, Guo L, et al. Inhibitors of protein geranylgeranyltransferase I and Rab geranylgeranyltransferase identified from a library of allenoate-derived compounds. J Biol Chem 2008;283:9571-9579
19. El Oualid F, Cohen LH, van der Marel GA, Overhand M. Inhibitors of protein: geranylgeranyl transferases. Curr Med Chem 2006;13:2385-2427 (Pubitemid 44184644)
20. 2-M enrichment in A549 cells. Cancer Res 1997;57:1846-1850.
21. Woo JT, Nakagawa H, Krecic AM, et al. Inhibitory effects of mevastatin and a geranylgeranyl transferase I inhibitor (GGTI-2166) on mononuclear osteoclast formation induced by receptor activator of NFκB ligand (RANKL) or tumor necrosis factor-α (TNF-α). Biochem Pharmacol 2005;69:87-95. (Pubitemid 39592875)
22. Bredel M, Pollack IF, Freund JM, Hamilton AD, Sebti SM. Inhibition of Ras and related G-proteins as a therapeutic strategy for blocking malignant glioma growth. Neurosurgery 1998;43:124-131 (Pubitemid 28287791)
23. Castellano S, Fiji HD, Kinderman SS, et al. Small-molecule inhibitors of protein geranylgeranyltransferase type I. J Am Chem Soc 2007;129:5843-5845 (Pubitemid 46748488)
24. Sun J, Blaskovich MA, Knowles D, et al. Antitumor efficacy of a novel class of non-thiol-containing peptidomimetic inhibitors of farnesyltransferase and geranylgeranyltransferase I: combination therapy with the cytotoxic agents cisplatin, Taxol, and gemcitabine. Cancer Res 1999;59:4919-4926 (Pubitemid 29472897)
25. Lobell RB, Omer CA, Abrams MT, et al. Evaluation of farnesyl:protein transferase and geranylgeranyl:protein transferase inhibitor combinations in preclinical models. Cancer Res 2001;61:8758-8768 (Pubitemid 34013888)
26. Seabra MC. Membrane association and targeting of prenylated Ras-like GTPases. Cell Signal 1998;10:167-172 (Pubitemid 28156067)
27. Lee JC, Kim DC, Gee MS, et al. Interleukin-12 inhibits angiogenesis and growth of transplanted but not in situ mouse mammary tumor virus-induced mammary carcinomas. Cancer Res 2002;62:747-755 (Pubitemid 34126950)
28. Park HJ, Kong D, Iruela-Arispe L, et al. 3-Hydroxy-3-methylglutaryl coenzyme A reductase inhibitors interfere with angiogenesis by inhibiting the geranylgeranylation of RhoA. Circ Res 2002;91:143-150 (Pubitemid 34827225)
29. Li X, Liu L, Tupper JC, et al. Inhibition of protein geranylgeranylation and RhoA/RhoA kinase pathway induces apoptosis in human endothelial cells. J Biol Chem 2002;277:15309-15316 (Pubitemid 34967792)
30. Noker P, Coward L, Gorman G, Jia L. Pharmacokinetics, tissue distribution, and excretion of GGTI-2418, an inhibitor of geranylgeranyl transferase I, in mice. AACR Meet Abstr 2008;2008:3305.
31. Dan HC, Jiang K, Coppola D, et al. Phosphatidylinositol-3-OH kinase/AKT and survivin pathways as critical targets for geranylgeranyltransferase I inhibitor-induced apoptosis. Oncogene 2004;23:706-715 (Pubitemid 38241271)
32. Campbell SL, Khosravi-Far R, Rossman KL, Clark GJ, Der CJ. Increasing complexity of Ras signaling. Oncogene 1998;17:1395-1413
33. Zohn IM, Campbell SL, Khosravi-Far R, Rossman KL, Der CJ. Rho family proteins and Ras transformation: the RHOad less traveled gets congested. Oncogene 1998;17:1415-1438